Submitted:
12 July 2024
Posted:
14 July 2024
You are already at the latest version
Abstract
Keywords:
1. Introduction
2. Patients and Methods
2.1. Patient Information and Ethical Considerations
2.2. Statistical Analyses
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
References
- Lemmens VE, Klaver YL, Verwaal VJ, et al.Predictors and survival of synchronous peritoneal carcinomatosis of colorectal origin: a population-based study. Int J Cancer. 2011; 128: 2717–25. [CrossRef]
- Jayne DG, Fook S, Loi C,et al. Peritoneal carcino matosis from colorectal cancer. Br J Surg. 2002; 89 :1545–1550.
- Segelman J, Granath F, Holm T, et al.Incidence, prevalence and risk factors for peritoneal carcinomatosis from colorectal cancer. Br J Surg.2012; 99 : 699–705.
- Behrenbruch C, Hollande F, Thomson B, et al. Treatment of peritoneal carcinomatosis with hyperthermic intraperitoneal chemotherapy in colorectal cancer. ANZ J. Surg.2017; 87: 665–670.
- Centers for Disease Control and Prevention: Cancer Stat Facts: Colorectal Cancer SEER 18 2011–2017. 2022. https://seer.cancer.gov/statfacts/html/colorect.html.
- Väyrynen V, Wirta E-V, Seppälä T, et al.Incidence and management of patients with colorectal cancer and synchronous and metachronous colorectal metastases: A population-based study. BJS Open.2020: 4: 685–692.
- Chua T, Liauw W, Chu F, et al. Viewing metastatic colorectal cancer as a curable chronic disease. Am J Clin Oncol.2012; 35: 77–80.
- Brucher BL, Piso P, Verwaal V, et al. Peritoneal carcinomatosis: Cytoreductive surgery and hipec—Overview and basics. Cancer Investig. 2012; 30:209–224.
- American Cancer Society: Colorectal Cancer Facts and Figures: 2020–2022. Atlanta, GA, American Cancer Society. 2020.
- Cummins KA, Russell GB, Votanopoulos KI, et al. Peritoneal dissemination from high-grade appendiceal cancer treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). J. Gastrointest. Oncol. 2016; 7: 3–9.
- Franko J, Shi Q, Goldman CD, et al.Treatment of colorectal peritoneal carcino matosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841. J Clin Oncol.2012; 30: 263–267.
- Yu HH, Yonemura Y,Hsieh MC, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for appendiceal goblet cell carcinomas with peritoneal carcinomatosis: Results from a single specialized center. Cancer Manag. Res. 2017; 9: 513–523. [CrossRef]
- Glehen O, Mohamed F, Gilly FN. Peritoneal carcinomatosis from digestive tract cancer: New management by cytoreductive surgery and intraperitoneal chemohyperthermia. Lancet Oncol. 2004;5,:219–228.
- Quenet F, Elias D, Roca L, et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2021 ; 22: 256-266.
- Pallas N , Karamveri C ,Kyziridis D , et al. Cytoreductive surgery and hyperthermic intraperitenoal chemotherapy (hipec ) for colorectal and appendiceal carcinomas with peritoneal carcinomatosis. J. BUON 2017, 22, 1547–1553.
- Elias D, Glehen O, Pocard M, et al. A comparative study of complete cytoreductive surgery plus intraperitoneal chemother apy to treat peritoneal dissemination from colon, rectum, small bowel, and nonpseudomyxoma appendix. Ann Surg. 2010; 251: 896–901.
- Fugazzola P, Moroni A, Agnoletti V, et al. Should we exclude patients with peritoneal carcinosis of colorectal origin and high PCI from CRS + HIPEC? Updates Surg. 2023; 75: 1819-1825.
- Spiliotis J, Kalles V, Kyriazanos I, et al. CRS and HIPEC in patients with peritoneal metastasis secondary to colorectal cancer: The small-bowel PCI score as a predictor of survival.Pleura Peritoneum. 2019; 30: 4.
- Livin M, Leonard D, Bachmann R, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal cancer: a 13 years-retrospective monocentric study.Acta Gastroenterol Belg. 2022; 85: 573-579.
- Mantovani A, Allavena P, Sica, A, et al. Cancer-related inflammation. Nature. 2008; 454: 436–444.
- Yang Y, Xu H, Zhou L, et al.Platelet to lymphocyte ratio is a predictive marker of prognosis and therapeutic e ect of postoperative chemotherapy in non-metastatic esophageal squamous cell carcinoma. Clin. Chim. Acta. 2018; 479: 160–165.
- Ying HQ, Deng QW, He BS,et al. The prognostic value of preoperative nlr, d-nlr, plr and lmr for predicting clinical outcome in surgical colorectal cancer patients. Med. Oncol. 2014; 31: 305.
- Szkandera J, Pichler M, Absenger G, et al. The elevated preoperative platelet to lymphocyte ratio predicts decreased time to recurrence in colon cancer patients. Am J Surg. 2014; 208: 210–214. [CrossRef]
- Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N. Engl. J. Med. 1999; 340: 448–454.
- Mallappa S, Sinha A, Gupta S, et al. Preoperative neutrophil to lymphocyte ratio >5 is a prognostic factor for recurrent colorectal cancer.Colorectal Dis. 2013; 15: 323-328.
- Choi W, Cleghorn M, Jiang H,et al. Preoperative neu trophil-to-lymphocyte ratio is a better prognostic serum bio marker than platelet-to-lymphocyte ratio in patients undergoing resection for nonmetastatic colorectal cancer. Ann Surg Oncol.2015;22: 603–613.
- He W, Yin C, Guo G,et al. Initial neutrophil lymphocyte ratio is superior to platelet lymphocyte ratio as an adverse prog nostic and predictive factor in metastatic colorectal cancer. Med Oncol.2013; 30: 439.
- Roxburgh C, McMillan D. Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. Future Oncol.2010; 6:149–163.
- Ding P, An X, Zhang R,et al. Elevated preoperative neu trophil to lymphocyte ratio predicts risk of recurrence following curative resection for stage IIA colon cancer. Int J Colorectal Dis.2010; 25: 1427–1433.
- Rangarajan K, Chandrakumaran K, Dayal S et al. The pre-operative neutrophil-lymphocyte ratio predicts overall and disease-free survival following cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with pseudomxyoma peritonei of appendiceal origin. Int. J. Hyperth. 2018; 34: 559–563.
- Yan Q, Ertao Z, Zhimei Z, et al. Systemic immune-inflammation index (SII): a more promising inflammation-based prognostic marker for patients with synchronic colorectal peritoneal carcinomatosis. J Cancer. 2020;11: 5264-5272.
- Bong TSH, Tan GHC, Chia C,et al. Preoperative platelet-lymphocyte ratio is an independent prognostic marker and superior to carcinoembryonic antigen in colorectal peritoneal carcinomatosis patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Int. J. Clin. Oncol. 2017; 22: 511–518.
- Medina Fernandez FJ, Munoz-Casares FC, Arjona-Sanchez A, et al. Postoperative time course and utility of inflammatory markers in patients with ovarian peritoneal carcinomatosis treated with neoadjuvant chemotherapy, cytoreductive surgery, and HIPEC. Ann Surg Oncol. 2015;22:1332-1340.
- Templeton AJ, Ace O, McNamara MG, et al. Prognostic role of platelet to lymphocyte ratio in solid tumors: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2014;23:1204–1212.
- Zager Y, Hoffman A, Dreznik Y, et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy in patients with peritoneal carcinomatosis from colorectal cancer: the prognostic impact of baseline neutrophil-lymphocyte, platelet-lymphocyte and lymphocyte-monocyte ratios. Surg Oncol. 2020; 35: 321–327.
- Clavien PA, Barkun J, de Oliveira ML, et al.The Clavien-Dindo classification of surgical complications: five-year experience.Ann Surg. 2009 ;250: 187-196.
- Bushati M, Rovers KP, Sommariva A, et al.The current practice of cytoreductive surgery and HIPEC for colorectal peritoneal metastases: Results of a worldwide web-based survey of the Peritoneal Surface Oncology Group International (PSOGI).Eur J Surg Oncol. 2018;44: 1942-1948. [CrossRef]
- Glehen O, Cotte E, Schreiber V, et al.Intraperitoneal chemohyperthermia and attempted cytoreductive surgery in patients with peritoneal carci nomatosis of colorectal origin. Br J Surg.2004; 91: 747–754.
- Glehen O, Kwiatkowski F, Sugarbaker PH, et al. Cytoreductive surgery combined with perio perative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institu tional study. J Clin Oncol.2004;22: 3284–3292.
- Shen P, Hawksworth J, Lovato J, et al.Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy with mitomycin C for peritoneal carcinomatosis from nonappendiceal colorectal carcinoma. Ann Surg Oncol.2004;11: 178–186.
- Royal R, Pingpank J.Diagnosis and management of peri toneal carcinomatosis arising from adenocarcinoma of the colon and rectum. Semin Oncol.2008; 35: 183–191.
- Verwaal V, van Tinteren H, van Ruth S, et al. Predicting the survival of patients with peritoneal carcino matosis of colorectal origin treated by aggressive cytoreduc tion and hyperthermic intraperitoneal chemotherapy. Br J Surg.2004; 91: 739–746.
- Narasimhan V, Tan S, Kong J,et al.Prognostic factors influencing survival in patients undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for isolated colorectal peritoneal metastases: a systematic review and meta-analysis.Colorectal Dis. 2020;22: 1482-1495.
- Rovers KP, Bakkers C, Nienhuijs SW et al.Perioperative Systemic Therapy vs Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Alone for Resectable Colorectal Peritoneal Metastases: A Phase 2 Randomized Clinical Trial.JAMA Surg. 2021;156: 710-720.
- Terzic´ J, Grivennikov S, Karin E, et al. Inflammation and colon cancer.Gastroenterology. 2010;138: 2101-2114.
- El Asmar A, Delcourt M, Kamden L,et al. Prognostic Value of Preoperative Serological Biomarkers in Patients Undergoing Curative-Intent Cytoreductive Surgery for Colorectal Cancer Peritoneal Metastases.Ann Surg Oncol. 2023;30: 1863-1869.
- Stojkovic Lalosevic M, Pavlovic Markovic A, et al.Combined Diagnostic Efficacy of Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Mean Platelet Volume (MPV) as Biomarkers of Systemic Inflammation in the Diagnosis of Colorectal Cancer.Dis Markers. 2019 ;17:6036979.
- Zhang J, Zhang HY, Li J, et al. The elevated NLR, PLR and PLT may predict the prognosis of patients with colorectal cancer: a systematic review and meta-analysis. Oncotarget. 2017;8: 68837-68846.
- Li MX, Liu XM, Zhang XF, et al. Prognostic role of neutrophil-to-lymphocyte ratio in colorectal cancer: a systematic review and meta-analysis.Int J Cancer. 2014 ;134: 2403-2413.
- Chan JC, Chan DL, Diakos CI, et al. The Lymphocyte-to-Monocyte Ratio is a Superior Predictor of Overall Survival in Comparison to Established Biomarkers of Resectable Colorectal Cancer.Ann Surg. 2017;265: 539-546.
- Tan JW, Tan GHC, Ng WYet al.High-grade complication is associated with poor overall survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.Int J Clin Oncol. 2020;25: 984-994.
- Halkia E, Kopanakis N, Nikolaou G, et al. Cytoreductive surgery and HIPEC for peritoneal carcinomatosis. A review on morbidity and mortality.J BUON. 2015 ;20 : 80-87.
- Inamoto S, Kawada K, Okamura R, et al. Prognostic impact of the combination of neutrophil-to-lymphocyte ratio and Glasgow prognostic score in colorectal cancer: A retrospective cohort study. Int. J. Colorectal Dis. 2019;34: 1303–1315. [CrossRef]
- Yamamoto T, Kawada K, Obama K.Inflammation-Related Biomarkers for the Prediction of Prognosis in Colorectal Cancer Patients.Int J Mol Sci. 2021 27;22:8002.
- Kwon HC, Kim SH, Oh SY, et al. Clinical significance of preoperative neutrophil-lymphocyte versus platelet-lymphocyte ratio in patients with operable colorectal cancer.Biomarkers. 2012 ;17: 216-22.
- Loh WL, Tan G,Chia C, et al. Prognostic significance of neutrophil- lymphocyte and platelet-lymphocyte ratio in predicting outcomes for peritoneal carcinomatosis patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Asian J Oncol. 2017;3: 28–34.
- Kim NY, Chun DH, Kim SY, et al. Prognostic Value of Systemic Inflammatory Indices, NLR, PLR, and MPV, for Predicting 1-Year Survival of Patients Undergoing Cytoreductive Surgery with HIPEC.J Clin Med.2019;8: 589.
| Variables | Total (n= 196) |
||
|---|---|---|---|
| Men (%) | 112 (57.1%) | ||
| Age (year) | |||
| Men | 57.3 (27-74) | ||
| Women | 56.9 (29-72) | ||
| Tumor origin | |||
| Colon | 152 (77.5%) | ||
| Rectum | 44 (22.4%) | ||
| Tumor site | |||
| Right Colon | 68 (44.7%) | ||
| Transvers Colon | 13 (8.5%) | ||
| Left Colon + Sigmoid | 71 (46.7%) | ||
| Histological Classification | |||
| Serous Adenocarcinoma | 140 (71.4%) | ||
| Mucinous adenocarcinoma | 49 (25%) | ||
| Signet-ring cell carcinoma | 4 (2%) | ||
| Adenosquamous carcinoma | 3 (1.5%) | ||
| Neoadjuvan Therapy | 153 (78%) | ||
| Data are presented as median (interquartile range) or n (%) | |||
| Variables | Total (n= 196) |
|---|---|
| PCI Score | 8 (3-18) |
| CC Score 0/1 | 189 (96.4%) |
| Operation Time (minute) | 420 (185-600) |
| Blood loss (ml) | 550 (200-4200) |
| FFP Transfusion (unit) | 1.2 (0-7) |
| Whole Blood Tranfusion (unit) | 2 (0-9) |
| Urine output (ml) | 800 (400-3500) |
| Hospitalization Time (day) | 8 (7-45) |
| Complication* | 22 (11.2%) |
| Reoperation due to anastomosis leakage | 10 (5.1%) |
| Pleural Effusion | 4 (2%) |
| Intraabdominal ascites | 3 (1.5%) |
| Hemofiltration due to renal failure | 2 (1%) |
| Cardiac arrythmia | 1 (0.5%) |
| Pulmonary Embolia | 1 (0.5%) |
| Covid-19 | 1 (0.5%) |
| Mortality | 8 (4.1%) |
| DFS (month) | 16 |
| OS (month) | 58 |
| 5-year Survival rate | 46% |
|
Data are presented as median (interquartile range) or n (%) PCI: Peritoneal Cancer Index CC: Completeness of cytoreduction FFP: Fresh Frozen Plasma DFS: Disease Free Survival OS: Overall Survival * Clavieon-Dindo Grade 3 and high | |
| Total (n =196) |
|
| Leukocyte (109/L) | 6.6 (4.2–8.9) |
| Hemoglobin (g/L) | 11 (97–140) |
| Platelet (109/L) | 310.000 (190 000–579.000) |
| Lymphocyte (109/L) | 1.68 ±. 49 |
| PLR | 150 (77-378) |
| NLR | 2.38 (3.01-21.6) |
| MPV (fL) | 8.09 (7.33–8.60) |
|
Data are presented as mean±SD or median (interquartile range) PLR: Platelet–lymphocyte ratio NLR: Neutrophil–lymphocyte ratio MPV: Mean Platelet Volume | |
| NLR | PLR | MPV | ||||
| <3.77 | ≥3.77 | <190 | ≥190 | <8 | ≥8 | |
| Grade 3 Complication | 8% | 20% | 21% | 10% | 9% | 18% |
| Disease Free Survival | - | - | 18 | 22 | - | - |
| Overall Survival | 58.2 | 22.1 | - | - | 40 | 17 |
| Univariate Analysis | |||
| HR | 95%CI | p value | |
| NLR (<3.77 vs ≥3.77) | 2.6 | 1.2-5.4 | <0.01 |
| PLR (<150 vs ≥150) | 1.9 | 1.05-3.55 | <0.03 |
| MPV (<8 vs ≥8) | 1.8 | 1.07-3.75 | <0.03 |
| Univariate Analysis | Multivariate Analysis | |||||
| HR | 95%CI | p value | HR | 95%CI | p value | |
| NLR (<3.77 vs ≥3.77) | - | - | - | 2.3 | 1.3-4.2 | <0.01 |
| PLR (<150 vs ≥150) | 1.9 | 1.06-3.54 | 0.03 | 2.0 | 1.03-3.9 | <0.05 |
| MPV (<8 vs ≥8) | - | - | - | 1.9 | 1.06-3.8 | <0.05 |
| Univariate Analysis | Multivariate Analysis | |||||
| HR | 95%CI | p value | HR | 95%CI | p value | |
| NLR (<3.77 vs ≥3.77) | 2.7 | 1.1-5.3 | <0.01 | 5.5 | 2.6-11.7 | <0.01 |
| PLR (<150 vs ≥150) | 2.0 | 1.03-3.9 | <0.05 | |||
| MPV (<8 vs ≥8) | 1.8 | 1.1-3.31 | <0.03 | |||
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).